Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Acadia Pharmaceuticals participates in a conference call with JPMorgan » 10:25
12/03/21
12/03
10:25
12/03/21
10:25
ACAD

Acadia Pharmaceuticals

$19.39 /

-0.53 (-2.66%)

US Large Cap Biotech…

US Large Cap Biotech Analyst Kasimov holds a conference call with CEO Davis on December 3 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$19.39 /

-0.53 (-2.66%)

ACAD Acadia Pharmaceuticals
$19.39 /

-0.53 (-2.66%)

11/09/21 Citi
Acadia Pharmaceuticals price target raised to $25 from $22 at Citi
11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
11/01/21 Guggenheim
Acadia upgraded to Buy at Guggenheim ahead of Rett study readout
11/01/21 Guggenheim
Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
ACAD Acadia Pharmaceuticals
$19.39 /

-0.53 (-2.66%)

ACAD Acadia Pharmaceuticals
$19.39 /

-0.53 (-2.66%)

Conference/Events
Acadia Pharmaceuticals participates in a conference call with JPMorgan » 04:55
12/03/21
12/03
04:55
12/03/21
04:55
ACAD

Acadia Pharmaceuticals

$19.92 /

+1.04 (+5.51%)

US Large Cap Biotech…

US Large Cap Biotech Analyst Kasimov holds a conference call with CEO Davis on December 3 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$19.92 /

+1.04 (+5.51%)

ACAD Acadia Pharmaceuticals
$19.92 /

+1.04 (+5.51%)

11/09/21 Citi
Acadia Pharmaceuticals price target raised to $25 from $22 at Citi
11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
11/01/21 Guggenheim
Acadia upgraded to Buy at Guggenheim ahead of Rett study readout
11/01/21 Guggenheim
Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
ACAD Acadia Pharmaceuticals
$19.92 /

+1.04 (+5.51%)

ACAD Acadia Pharmaceuticals
$19.92 /

+1.04 (+5.51%)

Yesterday
Conference/Events
Acadia Pharmaceuticals participates in a conference call with JPMorgan » 17:10
12/02/21
12/02
17:10
12/02/21
17:10
ACAD

Acadia Pharmaceuticals

$19.92 /

+1.04 (+5.51%)

US Large Cap Biotech…

US Large Cap Biotech Analyst Kasimov holds a conference call with CEO Davis on December 3 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$19.92 /

+1.04 (+5.51%)

ACAD Acadia Pharmaceuticals
$19.92 /

+1.04 (+5.51%)

11/09/21 Citi
Acadia Pharmaceuticals price target raised to $25 from $22 at Citi
11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
11/01/21 Guggenheim
Acadia upgraded to Buy at Guggenheim ahead of Rett study readout
11/01/21 Guggenheim
Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
ACAD Acadia Pharmaceuticals
$19.92 /

+1.04 (+5.51%)

ACAD Acadia Pharmaceuticals
$19.92 /

+1.04 (+5.51%)

Wednesday
Hot Stocks
Acadia Pharmaceuticals publishes data showing ADVANCE met its primary endpoint » 09:09
12/01/21
12/01
09:09
12/01/21
09:09
ACAD

Acadia Pharmaceuticals

$19.17 /

+0.31 (+1.64%)

Acadia Pharmaceuticals…

Acadia Pharmaceuticals announced that The Lancet Psychiatry published results from the Phase 2 ADVANCE study. ADVANCE was an international, 26-week, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of adjunctive pimavanserin treatment in outpatients with moderate-to-severe predominant negative symptoms of schizophrenia who had achieved control of positive symptoms with their ongoing antipsychotic treatment. ADVANCE met its primary endpoint, with significant improvement observed with pimavanserin for the change from baseline to week 26 on the Negative Symptoms Assessment-16 total score, compared with placebo. In a post hoc analysis, greater improvement in the NSA-16 total score compared to placebo was observed in the 53.8% of patients who received the highest pimavanserin dose of 34 mg. In the study, pimavanserin was well-tolerated with high completion rates of approximately 86% in both the pimavanserin and placebo treatment groups through 26 weeks and similar rates of adverse events between pimavanserin and placebo. Additionally, no clinically significant differences in vital signs, weight, metabolic syndrome or extrapyramidal symptoms were observed in the pimavanserin group compared to placebo. Serious adverse events were reported in 2.0% of patients on pimavanserin and 0.5% of patients on placebo and discontinuations due to adverse events were also low, 5.0% for pimavanserin and 3.0% for placebo.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$19.17 /

+0.31 (+1.64%)

ACAD Acadia Pharmaceuticals
$19.17 /

+0.31 (+1.64%)

11/09/21 Citi
Acadia Pharmaceuticals price target raised to $25 from $22 at Citi
11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
11/01/21 Guggenheim
Acadia upgraded to Buy at Guggenheim ahead of Rett study readout
11/01/21 Guggenheim
Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
ACAD Acadia Pharmaceuticals
$19.17 /

+0.31 (+1.64%)

ACAD Acadia Pharmaceuticals
$19.17 /

+0.31 (+1.64%)

Over a week ago
Conference/Events
CTAD Congress to hold a conference » 04:55
11/12/21
11/12
04:55
11/12/21
04:55
ALEC

Alector

$22.62 /

-2.225 (-8.96%)

, CRTX

Cortexyme

$14.55 /

-1.19 (-7.56%)

, ANVS

Annovis Bio

$32.95 /

+2.55 (+8.39%)

, INMB

INmune Bio

$14.61 /

+0.01 (+0.07%)

, ACAD

Acadia Pharmaceuticals

$20.69 /

+0.32 (+1.57%)

, NVO

Novo Nordisk

$113.38 /

+0.67 (+0.59%)

, BIIB

Biogen

$266.52 /

-0.45 (-0.17%)

, LLY

Eli Lilly

$261.68 /

-2.04 (-0.77%)

, PRTA

Prothena

$56.54 /

+0.42 (+0.75%)

, DNLI

Denali Therapeutics

$51.08 /

-1.19 (-2.28%)

, ABOS

Acumen

$13.47 /

-0.9 (-6.26%)

14th Clinical Trials on…

14th Clinical Trials on Alzheimer's Disease is being held in Boston on November 9-12. Webcast Link

ShowHide Related Items >><<
PRTA Prothena
$56.54 /

+0.42 (+0.75%)

NVO Novo Nordisk
$113.38 /

+0.67 (+0.59%)

LLY Eli Lilly
$261.68 /

-2.04 (-0.77%)

INMB INmune Bio
$14.61 /

+0.01 (+0.07%)

DNLI Denali Therapeutics
$51.08 /

-1.19 (-2.28%)

CRTX Cortexyme
$14.55 /

-1.19 (-7.56%)

BIIB Biogen
$266.52 /

-0.45 (-0.17%)

ANVS Annovis Bio
$32.95 /

+2.55 (+8.39%)

ALEC Alector
$22.62 /

-2.225 (-8.96%)

ACAD Acadia Pharmaceuticals
$20.69 /

+0.32 (+1.57%)

ABOS Acumen
$13.47 /

-0.9 (-6.26%)

ALEC Alector
$22.62 /

-2.225 (-8.96%)

09/27/21 William Blair
Alector initiated with an Outperform at William Blair
09/08/21 Stifel
Alector departures a surprise, but not much to read into, says Stifel
09/08/21 Goldman Sachs
Alector leadership changes 'come as a surprise,' says Goldman Sachs
07/30/21 H.C. Wainwright
Alector selloff on AL001 readout surprising, says H.C. Wainwright
CRTX Cortexyme
$14.55 /

-1.19 (-7.56%)

11/11/21 Citi
Cortexyme price target lowered to $2 from $5 at Citi
10/27/21
Fly Intel: Top five analyst downgrades
10/27/21 Canaccord
Cortexyme price target lowered to $75 from $150 at Canaccord
10/27/21 BofA
Cortexyme downgraded to Underperform at BofA after Alzheimer's trial miss
ANVS Annovis Bio
$32.95 /

+2.55 (+8.39%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
INMB INmune Bio
$14.61 /

+0.01 (+0.07%)

09/07/21 B. Riley
INmune Bio price target raised to $32 from $26 at B. Riley
07/14/21 B. Riley
INmune Bio price target raised to $34 from $29 at B. Riley
04/21/21 B. Riley
B. Riley starts 'under-followed' INmune Bio with Buy, $29 target
04/21/21 B. Riley
INmune Bio initiated with a Buy at B. Riley
ACAD Acadia Pharmaceuticals
$20.69 /

+0.32 (+1.57%)

11/09/21 Citi
Acadia Pharmaceuticals price target raised to $25 from $22 at Citi
11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
11/01/21 Guggenheim
Acadia upgraded to Buy at Guggenheim ahead of Rett study readout
11/01/21 Guggenheim
Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
NVO Novo Nordisk
$113.38 /

+0.67 (+0.59%)

11/11/21 UBS
Novo Nordisk price target raised to DKK 725 from DKK 630 at UBS
11/05/21 Deutsche Bank
Novo Nordisk price target raised to DKK 775 from DKK 735 at Deutsche Bank
11/04/21 Barclays
Novo Nordisk price target raised to DKK 750 from DKK 675 at Barclays
11/04/21 Credit Suisse
Novo Nordisk price target raised to DKK 670 from DKK 625 at Credit Suisse
BIIB Biogen
$266.52 /

-0.45 (-0.17%)

11/08/21 RBC Capital
RBC finds AERS data showing seizures, one death in patient on Biogen's Aduhelm
10/28/21 Cantor Fitzgerald
Biogen price target lowered to $259 from $316 at Cantor Fitzgerald
10/26/21 Mizuho
Biogen price target lowered to $270 from $300 at Mizuho
10/22/21 Canaccord
Biogen price target lowered to $390 from $423 at Canaccord
LLY Eli Lilly
$261.68 /

-2.04 (-0.77%)

10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
PRTA Prothena
$56.54 /

+0.42 (+0.75%)

09/27/21 Oppenheimer
Prothena price target raised to $100 from $90 at Oppenheimer
09/20/21 Fox Advisors
Prothena initiated with an Overweight at Fox Advisors
09/17/21 Cantor Fitzgerald
Prothena price target raised to $103 from $70 at Cantor Fitzgerald
DNLI Denali Therapeutics
$51.08 /

-1.19 (-2.28%)

11/05/21 Evercore ISI
Denali Therapeutics price target raised to $111 from $70 at Evercore ISI
09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
09/01/21 SMBC Nikko
Denali Therapeutics initiated with an Outperform at SMBC Nikko
07/26/21 Stifel
Denali DNL310 data 'noisy and trending in wrong direction,' says Stifel
ABOS Acumen
$13.47 /

-0.9 (-6.26%)

07/26/21 UBS
Acumen initiated with a Buy at UBS
07/26/21 Stifel
Acumen initiated with a Buy at Stifel
07/26/21 Credit Suisse
Acumen initiated with an Outperform at Credit Suisse
07/26/21 BofA
Acumen initiated with a Neutral at BofA
PRTA Prothena
$56.54 /

+0.42 (+0.75%)

NVO Novo Nordisk
$113.38 /

+0.67 (+0.59%)

LLY Eli Lilly
$261.68 /

-2.04 (-0.77%)

INMB INmune Bio
$14.61 /

+0.01 (+0.07%)

DNLI Denali Therapeutics
$51.08 /

-1.19 (-2.28%)

CRTX Cortexyme
$14.55 /

-1.19 (-7.56%)

BIIB Biogen
$266.52 /

-0.45 (-0.17%)

ALEC Alector
$22.62 /

-2.225 (-8.96%)

ACAD Acadia Pharmaceuticals
$20.69 /

+0.32 (+1.57%)

ABOS Acumen
$13.47 /

-0.9 (-6.26%)

  • 01
    Jul
  • 24
    Mar
LLY Eli Lilly
$261.68 /

-2.04 (-0.77%)

BIIB Biogen
$266.52 /

-0.45 (-0.17%)

NVO Novo Nordisk
$113.38 /

+0.67 (+0.59%)

LLY Eli Lilly
$261.68 /

-2.04 (-0.77%)

INMB INmune Bio
$14.61 /

+0.01 (+0.07%)

DNLI Denali Therapeutics
$51.08 /

-1.19 (-2.28%)

CRTX Cortexyme
$14.55 /

-1.19 (-7.56%)

BIIB Biogen
$266.52 /

-0.45 (-0.17%)

ANVS Annovis Bio
$32.95 /

+2.55 (+8.39%)

ALEC Alector
$22.62 /

-2.225 (-8.96%)

ACAD Acadia Pharmaceuticals
$20.69 /

+0.32 (+1.57%)

ABOS Acumen
$13.47 /

-0.9 (-6.26%)

LLY Eli Lilly
$261.68 /

-2.04 (-0.77%)

CRTX Cortexyme
$14.55 /

-1.19 (-7.56%)

BIIB Biogen
$266.52 /

-0.45 (-0.17%)

Conference/Events
CTAD Congress to hold a conference » 04:55
11/11/21
11/11
04:55
11/11/21
04:55
ALEC

Alector

$24.85 /

-0.71 (-2.78%)

, CRTX

Cortexyme

$15.74 /

-0.21 (-1.32%)

, ANVS

Annovis Bio

$30.40 /

-1.56 (-4.88%)

, INMB

INmune Bio

$14.60 /

-0.83 (-5.38%)

, ACAD

Acadia Pharmaceuticals

$20.37 /

-1.18 (-5.48%)

, NVO

Novo Nordisk

$112.71 /

-1.38 (-1.21%)

, BIIB

Biogen

$266.82 /

-3.21 (-1.19%)

, LLY

Eli Lilly

$264.65 /

+2.62 (+1.00%)

, PRTA

Prothena

$56.04 /

-0.53 (-0.94%)

, DNLI

Denali Therapeutics

$52.28 /

-0.71 (-1.34%)

, ABOS

Acumen

$14.24 /

-0.31 (-2.13%)

14th Clinical Trials on…

14th Clinical Trials on Alzheimer's Disease is being held in Boston on November 9-12. Webcast Link

ShowHide Related Items >><<
PRTA Prothena
$56.04 /

-0.53 (-0.94%)

NVO Novo Nordisk
$112.71 /

-1.38 (-1.21%)

LLY Eli Lilly
$264.65 /

+2.62 (+1.00%)

INMB INmune Bio
$14.60 /

-0.83 (-5.38%)

DNLI Denali Therapeutics
$52.28 /

-0.71 (-1.34%)

CRTX Cortexyme
$15.74 /

-0.21 (-1.32%)

BIIB Biogen
$266.82 /

-3.21 (-1.19%)

ANVS Annovis Bio
$30.40 /

-1.56 (-4.88%)

ALEC Alector
$24.85 /

-0.71 (-2.78%)

ACAD Acadia Pharmaceuticals
$20.37 /

-1.18 (-5.48%)

ABOS Acumen
$14.24 /

-0.31 (-2.13%)

ALEC Alector
$24.85 /

-0.71 (-2.78%)

09/27/21 William Blair
Alector initiated with an Outperform at William Blair
09/08/21 Stifel
Alector departures a surprise, but not much to read into, says Stifel
09/08/21 Goldman Sachs
Alector leadership changes 'come as a surprise,' says Goldman Sachs
07/30/21 H.C. Wainwright
Alector selloff on AL001 readout surprising, says H.C. Wainwright
CRTX Cortexyme
$15.74 /

-0.21 (-1.32%)

10/27/21
Fly Intel: Top five analyst downgrades
10/27/21 Canaccord
Cortexyme price target lowered to $75 from $150 at Canaccord
10/27/21 BofA
Cortexyme downgraded to Underperform at BofA after Alzheimer's trial miss
10/27/21 BofA
Cortexyme downgraded to Underperform from Neutral at BofA
ANVS Annovis Bio
$30.40 /

-1.56 (-4.88%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
INMB INmune Bio
$14.60 /

-0.83 (-5.38%)

09/07/21 B. Riley
INmune Bio price target raised to $32 from $26 at B. Riley
07/14/21 B. Riley
INmune Bio price target raised to $34 from $29 at B. Riley
04/21/21 B. Riley
B. Riley starts 'under-followed' INmune Bio with Buy, $29 target
04/21/21 B. Riley
INmune Bio initiated with a Buy at B. Riley
ACAD Acadia Pharmaceuticals
$20.37 /

-1.18 (-5.48%)

11/09/21 Citi
Acadia Pharmaceuticals price target raised to $25 from $22 at Citi
11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
11/01/21 Guggenheim
Acadia upgraded to Buy at Guggenheim ahead of Rett study readout
11/01/21 Guggenheim
Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
NVO Novo Nordisk
$112.71 /

-1.38 (-1.21%)

11/05/21 Deutsche Bank
Novo Nordisk price target raised to DKK 775 from DKK 735 at Deutsche Bank
11/04/21 Barclays
Novo Nordisk price target raised to DKK 750 from DKK 675 at Barclays
11/04/21 Credit Suisse
Novo Nordisk price target raised to DKK 670 from DKK 625 at Credit Suisse
11/04/21 JPMorgan
Novo Nordisk price target raised to DKK 800 from DKK 700 at JPMorgan
BIIB Biogen
$266.82 /

-3.21 (-1.19%)

11/08/21 RBC Capital
RBC finds AERS data showing seizures, one death in patient on Biogen's Aduhelm
10/28/21 Cantor Fitzgerald
Biogen price target lowered to $259 from $316 at Cantor Fitzgerald
10/26/21 Mizuho
Biogen price target lowered to $270 from $300 at Mizuho
10/22/21 Canaccord
Biogen price target lowered to $390 from $423 at Canaccord
LLY Eli Lilly
$264.65 /

+2.62 (+1.00%)

10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
PRTA Prothena
$56.04 /

-0.53 (-0.94%)

09/27/21 Oppenheimer
Prothena price target raised to $100 from $90 at Oppenheimer
09/20/21 Fox Advisors
Prothena initiated with an Overweight at Fox Advisors
09/17/21 Cantor Fitzgerald
Prothena price target raised to $103 from $70 at Cantor Fitzgerald
DNLI Denali Therapeutics
$52.28 /

-0.71 (-1.34%)

11/05/21 Evercore ISI
Denali Therapeutics price target raised to $111 from $70 at Evercore ISI
09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
09/01/21 SMBC Nikko
Denali Therapeutics initiated with an Outperform at SMBC Nikko
07/26/21 Stifel
Denali DNL310 data 'noisy and trending in wrong direction,' says Stifel
ABOS Acumen
$14.24 /

-0.31 (-2.13%)

07/26/21 UBS
Acumen initiated with a Buy at UBS
07/26/21 Stifel
Acumen initiated with a Buy at Stifel
07/26/21 Credit Suisse
Acumen initiated with an Outperform at Credit Suisse
07/26/21 BofA
Acumen initiated with a Neutral at BofA
PRTA Prothena
$56.04 /

-0.53 (-0.94%)

NVO Novo Nordisk
$112.71 /

-1.38 (-1.21%)

LLY Eli Lilly
$264.65 /

+2.62 (+1.00%)

INMB INmune Bio
$14.60 /

-0.83 (-5.38%)

DNLI Denali Therapeutics
$52.28 /

-0.71 (-1.34%)

CRTX Cortexyme
$15.74 /

-0.21 (-1.32%)

BIIB Biogen
$266.82 /

-3.21 (-1.19%)

ALEC Alector
$24.85 /

-0.71 (-2.78%)

ACAD Acadia Pharmaceuticals
$20.37 /

-1.18 (-5.48%)

ABOS Acumen
$14.24 /

-0.31 (-2.13%)

  • 01
    Jul
  • 24
    Mar
LLY Eli Lilly
$264.65 /

+2.62 (+1.00%)

BIIB Biogen
$266.82 /

-3.21 (-1.19%)

NVO Novo Nordisk
$112.71 /

-1.38 (-1.21%)

LLY Eli Lilly
$264.65 /

+2.62 (+1.00%)

INMB INmune Bio
$14.60 /

-0.83 (-5.38%)

DNLI Denali Therapeutics
$52.28 /

-0.71 (-1.34%)

CRTX Cortexyme
$15.74 /

-0.21 (-1.32%)

BIIB Biogen
$266.82 /

-3.21 (-1.19%)

ANVS Annovis Bio
$30.40 /

-1.56 (-4.88%)

ALEC Alector
$24.85 /

-0.71 (-2.78%)

ACAD Acadia Pharmaceuticals
$20.37 /

-1.18 (-5.48%)

ABOS Acumen
$14.24 /

-0.31 (-2.13%)

LLY Eli Lilly
$264.65 /

+2.62 (+1.00%)

CRTX Cortexyme
$15.74 /

-0.21 (-1.32%)

BIIB Biogen
$266.82 /

-3.21 (-1.19%)

Conference/Events
CTAD Congress to hold a conference » 04:55
11/10/21
11/10
04:55
11/10/21
04:55
ALEC

Alector

$25.49 /

+0.605 (+2.43%)

, CRTX

Cortexyme

$15.93 /

-1.16 (-6.79%)

, ANVS

Annovis Bio

$31.99 /

-5.48 (-14.63%)

, INMB

INmune Bio

$15.47 /

-0.04 (-0.26%)

, ACAD

Acadia Pharmaceuticals

$21.55 /

+1.97 (+10.06%)

, NVO

Novo Nordisk

$114.09 /

-0.58 (-0.51%)

, BIIB

Biogen

$269.95 /

-2.67 (-0.98%)

, LLY

Eli Lilly

$262.07 /

+1.525 (+0.59%)

, PRTA

Prothena

$56.47 /

-2.03 (-3.47%)

, DNLI

Denali Therapeutics

$52.99 /

-1.11 (-2.05%)

, ABOS

Acumen

$14.55 /

+0.07 (+0.48%)

14th Clinical Trials on…

14th Clinical Trials on Alzheimer's Disease is being held in Boston on November 9-12. Webcast Link

ShowHide Related Items >><<
PRTA Prothena
$56.47 /

-2.03 (-3.47%)

NVO Novo Nordisk
$114.09 /

-0.58 (-0.51%)

LLY Eli Lilly
$262.07 /

+1.525 (+0.59%)

INMB INmune Bio
$15.47 /

-0.04 (-0.26%)

DNLI Denali Therapeutics
$52.99 /

-1.11 (-2.05%)

CRTX Cortexyme
$15.93 /

-1.16 (-6.79%)

BIIB Biogen
$269.95 /

-2.67 (-0.98%)

ANVS Annovis Bio
$31.99 /

-5.48 (-14.63%)

ALEC Alector
$25.49 /

+0.605 (+2.43%)

ACAD Acadia Pharmaceuticals
$21.55 /

+1.97 (+10.06%)

ABOS Acumen
$14.55 /

+0.07 (+0.48%)

ALEC Alector
$25.49 /

+0.605 (+2.43%)

09/27/21 William Blair
Alector initiated with an Outperform at William Blair
09/08/21 Stifel
Alector departures a surprise, but not much to read into, says Stifel
09/08/21 Goldman Sachs
Alector leadership changes 'come as a surprise,' says Goldman Sachs
07/30/21 H.C. Wainwright
Alector selloff on AL001 readout surprising, says H.C. Wainwright
CRTX Cortexyme
$15.93 /

-1.16 (-6.79%)

10/27/21
Fly Intel: Top five analyst downgrades
10/27/21 Canaccord
Cortexyme price target lowered to $75 from $150 at Canaccord
10/27/21 BofA
Cortexyme downgraded to Underperform at BofA after Alzheimer's trial miss
10/27/21 BofA
Cortexyme downgraded to Underperform from Neutral at BofA
ANVS Annovis Bio
$31.99 /

-5.48 (-14.63%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
INMB INmune Bio
$15.47 /

-0.04 (-0.26%)

09/07/21 B. Riley
INmune Bio price target raised to $32 from $26 at B. Riley
07/14/21 B. Riley
INmune Bio price target raised to $34 from $29 at B. Riley
04/21/21 B. Riley
B. Riley starts 'under-followed' INmune Bio with Buy, $29 target
04/21/21 B. Riley
INmune Bio initiated with a Buy at B. Riley
ACAD Acadia Pharmaceuticals
$21.55 /

+1.97 (+10.06%)

11/09/21 Citi
Acadia Pharmaceuticals price target raised to $25 from $22 at Citi
11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
11/01/21 Guggenheim
Acadia upgraded to Buy at Guggenheim ahead of Rett study readout
11/01/21 Guggenheim
Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
NVO Novo Nordisk
$114.09 /

-0.58 (-0.51%)

11/05/21 Deutsche Bank
Novo Nordisk price target raised to DKK 775 from DKK 735 at Deutsche Bank
11/04/21 Barclays
Novo Nordisk price target raised to DKK 750 from DKK 675 at Barclays
11/04/21 Credit Suisse
Novo Nordisk price target raised to DKK 670 from DKK 625 at Credit Suisse
11/04/21 JPMorgan
Novo Nordisk price target raised to DKK 800 from DKK 700 at JPMorgan
BIIB Biogen
$269.95 /

-2.67 (-0.98%)

11/08/21 RBC Capital
RBC finds AERS data showing seizures, one death in patient on Biogen's Aduhelm
10/28/21 Cantor Fitzgerald
Biogen price target lowered to $259 from $316 at Cantor Fitzgerald
10/26/21 Mizuho
Biogen price target lowered to $270 from $300 at Mizuho
10/22/21 Canaccord
Biogen price target lowered to $390 from $423 at Canaccord
LLY Eli Lilly
$262.07 /

+1.525 (+0.59%)

10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
PRTA Prothena
$56.47 /

-2.03 (-3.47%)

09/27/21 Oppenheimer
Prothena price target raised to $100 from $90 at Oppenheimer
09/20/21 Fox Advisors
Prothena initiated with an Overweight at Fox Advisors
09/17/21 Cantor Fitzgerald
Prothena price target raised to $103 from $70 at Cantor Fitzgerald
DNLI Denali Therapeutics
$52.99 /

-1.11 (-2.05%)

11/05/21 Evercore ISI
Denali Therapeutics price target raised to $111 from $70 at Evercore ISI
09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
09/01/21 SMBC Nikko
Denali Therapeutics initiated with an Outperform at SMBC Nikko
07/26/21 Stifel
Denali DNL310 data 'noisy and trending in wrong direction,' says Stifel
ABOS Acumen
$14.55 /

+0.07 (+0.48%)

07/26/21 UBS
Acumen initiated with a Buy at UBS
07/26/21 Stifel
Acumen initiated with a Buy at Stifel
07/26/21 Credit Suisse
Acumen initiated with an Outperform at Credit Suisse
07/26/21 BofA
Acumen initiated with a Neutral at BofA
PRTA Prothena
$56.47 /

-2.03 (-3.47%)

NVO Novo Nordisk
$114.09 /

-0.58 (-0.51%)

LLY Eli Lilly
$262.07 /

+1.525 (+0.59%)

INMB INmune Bio
$15.47 /

-0.04 (-0.26%)

DNLI Denali Therapeutics
$52.99 /

-1.11 (-2.05%)

CRTX Cortexyme
$15.93 /

-1.16 (-6.79%)

BIIB Biogen
$269.95 /

-2.67 (-0.98%)

ALEC Alector
$25.49 /

+0.605 (+2.43%)

ACAD Acadia Pharmaceuticals
$21.55 /

+1.97 (+10.06%)

ABOS Acumen
$14.55 /

+0.07 (+0.48%)

  • 01
    Jul
  • 24
    Mar
LLY Eli Lilly
$262.07 /

+1.525 (+0.59%)

BIIB Biogen
$269.95 /

-2.67 (-0.98%)

NVO Novo Nordisk
$114.09 /

-0.58 (-0.51%)

LLY Eli Lilly
$262.07 /

+1.525 (+0.59%)

INMB INmune Bio
$15.47 /

-0.04 (-0.26%)

DNLI Denali Therapeutics
$52.99 /

-1.11 (-2.05%)

CRTX Cortexyme
$15.93 /

-1.16 (-6.79%)

BIIB Biogen
$269.95 /

-2.67 (-0.98%)

ANVS Annovis Bio
$31.99 /

-5.48 (-14.63%)

ALEC Alector
$25.49 /

+0.605 (+2.43%)

ACAD Acadia Pharmaceuticals
$21.55 /

+1.97 (+10.06%)

ABOS Acumen
$14.55 /

+0.07 (+0.48%)

LLY Eli Lilly
$262.07 /

+1.525 (+0.59%)

CRTX Cortexyme
$15.93 /

-1.16 (-6.79%)

BIIB Biogen
$269.95 /

-2.67 (-0.98%)

Conference/Events
CTAD Congress to hold a conference » 08:44
11/09/21
11/09
08:44
11/09/21
08:44
ALEC

Alector

$24.90 /

-0.24 (-0.95%)

, CRTX

Cortexyme

$17.10 /

+0.42 (+2.52%)

, ANVS

Annovis Bio

$37.47 /

+1.03 (+2.83%)

, INMB

INmune Bio

$15.50 /

+1.245 (+8.73%)

, ACAD

Acadia Pharmaceuticals

$19.58 /

-0.455 (-2.27%)

, NVO

Novo Nordisk

$114.67 /

+1.265 (+1.12%)

, BIIB

Biogen

$272.57 /

-6.17 (-2.21%)

, LLY

Eli Lilly

$260.55 /

-4.505 (-1.70%)

, PRTA

Prothena

$58.50 /

-0.25 (-0.43%)

, DNLI

Denali Therapeutics

$54.13 /

-0.8 (-1.46%)

, ABOS

Acumen

$14.58 /

-0.34 (-2.28%)

14th Clinical Trials on…

14th Clinical Trials on Alzheimer's Disease is being held in Boston on November 9-12. Webcast Link

ShowHide Related Items >><<
PRTA Prothena
$58.50 /

-0.25 (-0.43%)

NVO Novo Nordisk
$114.67 /

+1.265 (+1.12%)

LLY Eli Lilly
$260.55 /

-4.505 (-1.70%)

INMB INmune Bio
$15.50 /

+1.245 (+8.73%)

DNLI Denali Therapeutics
$54.13 /

-0.8 (-1.46%)

CRTX Cortexyme
$17.10 /

+0.42 (+2.52%)

BIIB Biogen
$272.57 /

-6.17 (-2.21%)

ANVS Annovis Bio
$37.47 /

+1.03 (+2.83%)

ALEC Alector
$24.90 /

-0.24 (-0.95%)

ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

ABOS Acumen
$14.58 /

-0.34 (-2.28%)

ALEC Alector
$24.90 /

-0.24 (-0.95%)

09/27/21 William Blair
Alector initiated with an Outperform at William Blair
09/08/21 Stifel
Alector departures a surprise, but not much to read into, says Stifel
09/08/21 Goldman Sachs
Alector leadership changes 'come as a surprise,' says Goldman Sachs
07/30/21 H.C. Wainwright
Alector selloff on AL001 readout surprising, says H.C. Wainwright
CRTX Cortexyme
$17.10 /

+0.42 (+2.52%)

10/27/21
Fly Intel: Top five analyst downgrades
10/27/21 Canaccord
Cortexyme price target lowered to $75 from $150 at Canaccord
10/27/21 BofA
Cortexyme downgraded to Underperform at BofA after Alzheimer's trial miss
10/27/21 BofA
Cortexyme downgraded to Underperform from Neutral at BofA
ANVS Annovis Bio
$37.47 /

+1.03 (+2.83%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
INMB INmune Bio
$15.50 /

+1.245 (+8.73%)

09/07/21 B. Riley
INmune Bio price target raised to $32 from $26 at B. Riley
07/14/21 B. Riley
INmune Bio price target raised to $34 from $29 at B. Riley
04/21/21 B. Riley
B. Riley starts 'under-followed' INmune Bio with Buy, $29 target
04/21/21 B. Riley
INmune Bio initiated with a Buy at B. Riley
ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

11/09/21 Citi
Acadia Pharmaceuticals price target raised to $25 from $22 at Citi
11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
11/01/21 Guggenheim
Acadia upgraded to Buy at Guggenheim ahead of Rett study readout
11/01/21 Guggenheim
Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
NVO Novo Nordisk
$114.67 /

+1.265 (+1.12%)

11/05/21 Deutsche Bank
Novo Nordisk price target raised to DKK 775 from DKK 735 at Deutsche Bank
11/04/21 Barclays
Novo Nordisk price target raised to DKK 750 from DKK 675 at Barclays
11/04/21 Credit Suisse
Novo Nordisk price target raised to DKK 670 from DKK 625 at Credit Suisse
11/04/21 JPMorgan
Novo Nordisk price target raised to DKK 800 from DKK 700 at JPMorgan
BIIB Biogen
$272.57 /

-6.17 (-2.21%)

11/08/21 RBC Capital
RBC finds AERS data showing seizures, one death in patient on Biogen's Aduhelm
10/28/21 Cantor Fitzgerald
Biogen price target lowered to $259 from $316 at Cantor Fitzgerald
10/26/21 Mizuho
Biogen price target lowered to $270 from $300 at Mizuho
10/22/21 Canaccord
Biogen price target lowered to $390 from $423 at Canaccord
LLY Eli Lilly
$260.55 /

-4.505 (-1.70%)

10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
PRTA Prothena
$58.50 /

-0.25 (-0.43%)

09/27/21 Oppenheimer
Prothena price target raised to $100 from $90 at Oppenheimer
09/20/21 Fox Advisors
Prothena initiated with an Overweight at Fox Advisors
09/17/21 Cantor Fitzgerald
Prothena price target raised to $103 from $70 at Cantor Fitzgerald
DNLI Denali Therapeutics
$54.13 /

-0.8 (-1.46%)

11/05/21 Evercore ISI
Denali Therapeutics price target raised to $111 from $70 at Evercore ISI
09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
09/01/21 SMBC Nikko
Denali Therapeutics initiated with an Outperform at SMBC Nikko
07/26/21 Stifel
Denali DNL310 data 'noisy and trending in wrong direction,' says Stifel
ABOS Acumen
$14.58 /

-0.34 (-2.28%)

07/26/21 UBS
Acumen initiated with a Buy at UBS
07/26/21 Stifel
Acumen initiated with a Buy at Stifel
07/26/21 Credit Suisse
Acumen initiated with an Outperform at Credit Suisse
07/26/21 BofA
Acumen initiated with a Neutral at BofA
PRTA Prothena
$58.50 /

-0.25 (-0.43%)

NVO Novo Nordisk
$114.67 /

+1.265 (+1.12%)

LLY Eli Lilly
$260.55 /

-4.505 (-1.70%)

INMB INmune Bio
$15.50 /

+1.245 (+8.73%)

DNLI Denali Therapeutics
$54.13 /

-0.8 (-1.46%)

CRTX Cortexyme
$17.10 /

+0.42 (+2.52%)

BIIB Biogen
$272.57 /

-6.17 (-2.21%)

ALEC Alector
$24.90 /

-0.24 (-0.95%)

ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

ABOS Acumen
$14.58 /

-0.34 (-2.28%)

  • 01
    Jul
  • 24
    Mar
LLY Eli Lilly
$260.55 /

-4.505 (-1.70%)

BIIB Biogen
$272.57 /

-6.17 (-2.21%)

NVO Novo Nordisk
$114.67 /

+1.265 (+1.12%)

LLY Eli Lilly
$260.55 /

-4.505 (-1.70%)

INMB INmune Bio
$15.50 /

+1.245 (+8.73%)

DNLI Denali Therapeutics
$54.13 /

-0.8 (-1.46%)

CRTX Cortexyme
$17.10 /

+0.42 (+2.52%)

BIIB Biogen
$272.57 /

-6.17 (-2.21%)

ANVS Annovis Bio
$37.47 /

+1.03 (+2.83%)

ALEC Alector
$24.90 /

-0.24 (-0.95%)

ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

ABOS Acumen
$14.58 /

-0.34 (-2.28%)

LLY Eli Lilly
$260.55 /

-4.505 (-1.70%)

CRTX Cortexyme
$17.10 /

+0.42 (+2.52%)

BIIB Biogen
$272.57 /

-6.17 (-2.21%)

Recommendations
Acadia Pharmaceuticals price target raised to $25 from $22 at Citi » 06:15
11/09/21
11/09
06:15
11/09/21
06:15
ACAD

Acadia Pharmaceuticals

$19.58 /

-0.455 (-2.27%)

Citi analyst Neena…

Citi analyst Neena Bitritto-Garg raised the firm's price target on Acadia Pharmaceuticals to $25 from $22 and keeps a Neutral rating on the shares. The analyst is "incrementally positive" post the Q3 print due to a modest Nuplazid beat and a more focused regulatory strategy in DRP.

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
11/01/21 Guggenheim
Acadia upgraded to Buy at Guggenheim ahead of Rett study readout
11/01/21 Guggenheim
Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
10/14/21 Morgan Stanley
Acadia downgraded to Equal Weight in SMID-cap biotech shake-up at Morgan Stanley
ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

Hot Stocks
Acadia narrows FY21 NUPLAID revenue view to $480M-$500M from $480M-$515M  16:24
11/08/21
11/08
16:24
11/08/21
16:24
ACAD

Acadia Pharmaceuticals

$19.58 /

-0.455 (-2.27%)

 
ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

11/04/21 Stifel
Karuna Therapeutics price target raised to $185 from $154 at Stifel
11/01/21 Guggenheim
Acadia upgraded to Buy at Guggenheim ahead of Rett study readout
11/01/21 Guggenheim
Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
10/14/21 Morgan Stanley
Acadia downgraded to Equal Weight in SMID-cap biotech shake-up at Morgan Stanley
ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

ACAD Acadia Pharmaceuticals
$19.58 /

-0.455 (-2.27%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.